The Influence of Antipsychotic Treatment on Brain Reward System Reactivity in Schizophrenia Patients

Abstract

Introduction:Neuroleptic dysphoria is discussed as a serious side effect of antipsychotic medication. One aspect of this condition, a reduced motivation to reach potential rewards, might be induced by a blockade of striatal D2 receptors resulting in a reduced reactivity of the brain reward system. However, since this D2 antagonistic effect is higher for typical than atypical antipsychotics, typical antipsychotics should induce a stronger dampening of brain reward system activation. This hypothesis was tested in an event related functional magnetic resonance imaging study.

Methods:A monetary reward paradigm was presented to 30 schizophrenia patients, who were treated with typical or atypical antipsychotics or a combination of both. Hemodynamic responses were analyzed during the anticipation and the reception of the reward.

Results:Activation of the right ventral striatum, a core region of the brain reward system, was lower in patients treated with typical antipsychotics but only during the anticipation and not the delivery of a monetary reward.

Discussion:This result indicates that a D2 associated reduction of brain reward system reactivity might be the neurobiological correlate of reduced motivation observed in the context of neuroleptic dysphoria. Using typical antipsychotics might worsen this effect, increasing the negative symptomatology of schizophrenia patients.

References

• 1 Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?.  Brain Res Brain Res Rev. 1998;  28 309-369
• 2 Juckel G, Schlagenhauf F, Koslowski M. et al . Dysfunction of ventral striatal reward prediction in schizophrenia.  Neuroimage. 2006;  29 409-416
• 3 Karow A, Schnedler D, Naber D. What would the patient choose?. Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiatry. 2006;  39 47-51
• 4 Kirsch P, Reuter M, Mier D. et al . Imaging gene-substance interactions: the effect of the DRD₂ TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward.  Neurosci Lett. 2006;  405 196-201
• 5 Kirsch P, Schienle A, Stark R. et al . Anticipation of reward in a nonaversive differential conditioning paradigm and the brain reward system: an event-related fMRI study.  Neuroimage. 2003;  20 1086-1095
• 6 Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance.  Acta Psychiatr Scand Suppl. 2005;  29-34
• 7 Raedler TJ, Schreiner A, Naber D. et al . Gender-specific effects in the treatment of acute schizophrenia with risperidone.  Pharmacopsychiatry. 2006;  39 171-174
• 8 Schultz W. Getting formal with dopamine and reward.  Neuron. 2002;  36 241-263
• 9 Singh MM, Smith JM. Kinetics and dynamics of response to haloperidol in acute schizophrenia-A longitudinal study of the therapeutic process.  Compr Psychiatry. 1973;  14 393-414
• 10 Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis.  Psychopharmacology (Berl). 2004;  171 121-132
• 11 Voruganti LN, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia-findings from an in vivo SPECT study.  Schizophr Res. 2006;  88 179-186

Correspondence